INTRODUCTION {#s1}
============

Bladder cancer is the ninth most common cancer worldwide. Approximately 430,000 patients are diagnosed and 165,000 patients die from it annually \[[@R1]\]. Approximately 25% of newly diagnosed cases are muscle invasive bladder cancer (MIBC, ≥ T2), and radical cystectomy is the standard treatment. Other non-muscle invasive bladder cancers (NMIBCs) include stage Ta noninvasive papillary carcinomas and stage T1 tumors that invade the subepithelial connective tissue. The gold standard treatment of NMIBC is transurethral resection of bladder tumor (TURBT) and intravesical Bacillus Calmette--Guérin (BCG) installation. However, 30%--70% of patients experience a recurrence after initial treatment, and 25%--60% progress to MIBC.

As the incidence and survival of bladder cancer increase, the importance of treatment follow-up and predicting the risk of recurrence and progression of individual patients also increases. The outcome of T1 bladder cancer can range from no recurrence to rapid progression to MIBC and metastasis. As progression has a poor prognosis, it is important to distinguish patients who would benefit from early cystectomy and those best managed by bladder-preserving treatments. Currently, such group assignment is challenging. The use of clinical and pathological variables, such as tumor size and number and presence of a carcinoma *in situ* (CIS), to estimate MIBC progression risk has been evaluated \[[@R2]\], but it is difficult to estimate individual prognosis. Characterizing bladder cancer as low or high grade using two-tier criteria of the European Treatment Guidelines or the 2004 World Health Organization classification is difficult, and distinguishing Ta and T1 bladder cancer is problematic because of interobserver error \[[@R3]\]. Tumor markers, such as bcl-2, p53, Ki67, and CK20, are currently under study, but none are in routine clinical use at this time.

Ki-67 is a nuclear protein that is associated with ribosomal RNA transcription and is a marker of cellular proliferation \[[@R4]\]. It is strongly expressed in the growth fraction of cancer cells, and the presence of Ki-67-positive tumor cells indicates a poor survival and recurrence prognosis in prostate and breast cancer and nephroblastoma \[[@R5]\]. Ki-67 has not been confirmed as a poor prognosis marker in NMIBC patients because the reported thresholds of positivity and the immunochemical staining methods vary, making direct comparisons difficult \[[@R6]\]. An expert consensus panel has found that markers, such as Ki-67 and p53, can predict the recurrence and progression of bladder cancer, but the inconsistency of available data indicates their unreliability \[[@R7]\]. This meta-analysis was conducted to increase our understanding of the prognostic significance of Ki-67 in NMIBC patients.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The characteristics of the 39 selected studies are described in Tables [1](#T1){ref-type="table"}--[3](#T3){ref-type="table"}. They were published between 1997 and 2015, 17 were conducted in Asian countries, 17 were conducted in Europe, and five were conducted in America. All but two studies were retrospective, 19 included \< 100 patients, 20 included ≥ 100 patients, follow-up ranged from 1 to 267 months, and five studies did not report the duration of follow-up.

###### Main characteristics of the eligible studies

  Study                         Year   Country       Recruit period   Study design    Inclusion and exclusion criteria   Consecutive patients   Definition of outcome
  ----------------------------- ------ ------------- ---------------- --------------- ---------------------------------- ---------------------- -----------------------
  Asakura \[[@R20]\]            1997   Japan         1984--1993       Retrospective   Yes                                NA                     No
  Lee \[[@R21]\]                1997   Korea         1988--1993       Retrospective   Yes                                NA                     No
  Pfister \[[@R22]\]            1999   Canada        1990--1992       Retrospective   Yes                                NA                     No
  Tomobe \[[@R23]\]             1999   Japan         1989--1994       Retrospective   No                                 NA                     No
  Wu \[[@R24]\]                 2000   Taiwan        1990--1997       Retrospective   Yes                                NA                     No
  Blanchet \[[@R25]\]           2001   France        1989--1990       Prospective     No                                 Yes                    Yes
  Kamai \[[@R26]\]              2001   Japan         1987--1997       Retrospective   No                                 Yes                    No
  Kilicli-Camur \[[@R27]\]      2002   Turkey        NA               Retrospective   No                                 NA                     Yes
  Sgambato \[[@R28]\]           2002   Italy         1990--1995       Retrospective   Yes                                Yes                    Yes
  Yan \[[@R29]\]                2002   USA           1994--1999       Retrospective   Yes                                Yes                    No
  Dybowski \[[@R30]\]           2003   Poland        1994--1995       Retrospective   Yes                                NA                     No
  Santos \[[@R31]\]             2003   Portugal      1989--1996       Retrospective   Yes                                Yes                    Yes
  Su \[[@R32]\]                 2003   Japan         NA               Retrospective   No                                 NA                     Yes
  Mhawech \[[@R33]\]            2004   Switzerland   1997--2000       Retrospective   Yes                                NA                     Yes
  Krüger \[[@R34]\]             2005   Germany       1987--1999       Retrospective   Yes                                Yes                    Yes
  Theodoropoulos \[[@R35]\]     2005   Greece        1993--2003       Retrospective   Yes                                No                     Yes
  Gonzalez-Campora \[[@R36]\]   2006   Spain         1991--1997       Retrospective   No                                 Yes                    Yes
  Quintero \[[@R37]\]           2006   Spain         1990--1994       Retrospective   No                                 Yes                    Yes
  Yin \[[@R38]\]                2006   China         NA               Retrospective   No                                 Yes                    No
  Maeng \[[@R39]\]              2010   Korea         2001--2007       Retrospective   No                                 NA                     No
  Miyake \[[@R40]\]             2010   Japan         2000--2005       Retrospective   No                                 Yes                    No
  Seo \[[@R41]\]                2010   Korea         2001--2007       Retrospective   Yes                                NA                     Yes
  van Rhijn \[[@R10]\]          2010   Netherlands   NA               Retrospective   No                                 NA                     Yes
  Behnsawy \[[@R42]\]           2011   Japan         2000--2007       Retrospective   No                                 Yes                    No
  Wosnitzer \[[@R43]\]          2011   USA           NA               Retrospective   No                                 NA                     No
  Acikalin \[[@R6]\]            2012   Turkey        1996--2007       Retrospective   No                                 NA                     Yes
  Chen \[[@R11]\]               2012   China         NA               Retrospective   No                                 NA                     Yes
  Ogata \[[@R44]\]              2012   Brazil        2005--2010       Retrospective   Yes                                NA                     No
  Oderda \[[@R45]\]             2013   Italy         1994--2004       Prospective     No                                 NA                     Yes
  Okazoe \[[@R46]\]             2013   Japan         2006--2009       Retrospective   No                                 NA                     No
  Park \[[@R47]\]               2013   Korea         1990--2007       Retrospective   No                                 NA                     Yes
  Ruan \[[@R48]\]               2013   China         2007--2010       Retrospective   Yes                                NA                     No
  Ben Abdelkrim \[[@R14]\]      2014   Tunisia       2001--2003       Retrospective   No                                 NA                     Yes
  Bertz \[[@R18]\]              2014   Germany       1989--2006       Retrospective   No                                 NA                     No
  Ding \[[@R15]\]               2014   China         2000--2010       Retrospective   No                                 NA                     Yes
  Mangrud \[[@R49]\]            2014   Norway        2002--2006       Retrospective   Yes                                Yes                    Yes
  Pan \[[@R50]\]                2014   Taiwan        1991--2005       Retrospective   No                                 NA                     Yes
  Özyalvaçli \[[@R16]\]         2015   Turkey        2005--2013       Retrospective   No                                 Yes                    Yes
  Poyet \[[@R17]\]              2015   Switzerland   1990--2006       Retrospective   No                                 Yes                    Yes

NA: not available.

###### Patient characteristics of the eligible studies

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         No. of patients   Median age, range (years)   Gender\               Intravesical therapy (no.)                                                        Median follow-up, range (months)
                                                                              (male/female)                                                                                           
  ----------------------------- ----------------- --------------------------- --------------------- --------------------------------------------------------------------------------- ----------------------------------
  Asakura \[[@R20]\]            104               63 (mean), 28--90           78/26                 Chemotherapy (6)                                                                  42 (mean), 3--134

  Lee \[[@R21]\]                32                NA, 30--81                  28/4                  BCG (32)                                                                          NA

  Pfister \[[@R22]\]            244               65.1 (mean), NA             NA                    No                                                                                47 (mean), NA

  Tomobe \[[@R23]\]             50                63.9 (mean), 22--88         43/7                  Chemotherapy or BCG (32)                                                          44 (mean), 5--80

  Wu \[[@R24]\]                 86                NA                          NA                    NA                                                                                NA

  Blanchet \[[@R25]\]           70                62.6 (mean), 21--84         66/4                  BCG (57)                                                                          64, 12--111

  Kamai \[[@R26]\]              86                NA                          NA                    MMC, doxorubicin or BCG (NA)                                                      50, 3--124

  Kilicli-Camur \[[@R27]\]      118               60.2 (mean), 29--86         NA                    NA                                                                                31.4 (mean), 24--60

  Sgambato \[[@R28]\]           96                68 (mean), 29--92           83/13                 BCG (NA)                                                                          50 (mean), 24--102

  Yan \[[@R29]\]                270               71 (mean), NA               196/71, unknown (3)   BCG (66)                                                                          19, (1--54)

  Dybowski \[[@R30]\]           45                NA                          NA                    NA                                                                                64, 1--82

  Santos \[[@R31]\]             159               66, 21--88                  115/44                Chemotherapy (65), BCG (17)                                                       46.5, 4--123

  Su \[[@R32]\]                 79                64, 34--91                  66/13                 MMC or Adriamycin (74)                                                            48.7 (mean), 4--78

  Mhawech \[[@R33]\]            49                70.3 (mean), 52--90         44/5                  BCG (7)                                                                           12, 3--77

  Krüger \[[@R34]\]             73                68, NA                      60/13                 BCG (73)                                                                          NA

  Theodoropoulos \[[@R35]\]     140               69, 23--89                  107/33                Epirubicin or BCG (114)                                                           41, 8--131

  Gonzalez-Campora \[[@R36]\]   147               66 (mean), 30--95           127/20                BCG (NA)                                                                          75 (mean), 5--12 yr

  Quintero \[[@R37]\]           164               61 (mean), 29--93           143/21                BCG (NA)                                                                          75, 60--144

  Yin \[[@R38]\]                101               NA                          81/20                 BCG (101)                                                                         54, 20--68.6\
                                                                                                                                                                                      (10--90% percentiles)

  Maeng \[[@R39]\]              55                67 (mean), 33--84           40/15                 NA                                                                                26.2 (mean), 3--70

  Miyake \[[@R40]\]             109               68.5 (mea), 36--94          19/14                 Anthracycline (16), doxorubicin (1), epirubicin (13), pirarubicin (2), BCG (19)   48, 1--99

  Seo \[[@R41]\]                129               64.2 (38--88)               104/25                MMC (129)                                                                         48.6 (mean), 6.1--96

  van Rhijn \[[@R10]\]          230               65.1 (mean), NA             175/55                NA                                                                                8.6 yr, 6.6--11.3 yr (IQR)

  Behnsawy \[[@R42]\]           161               NA                          137/24                Unknown regimen (49)                                                              47, 13--93

  Wosnitzer \[[@R43]\]          32                70.3, 44--89                25/7                  Docetaxel (17), nanoparticle albumin-bound docetaxel (15)                         22, 11--75

  Acikalin \[[@R6]\]            68                63, 35--85                  66/2                  NA                                                                                51, 12--132

  Chen \[[@R11]\]               72                61.3 (mean), 27--87         58/14                 MMC, epirubicin, pirarubicin (NA)                                                 63.4 (mean), 16--93

  Ogata \[[@R44]\]              43                70, 39--85                  35/8                  NA                                                                                NA, 12--71

  Oderda \[[@R45]\]             192               73.2 (mean), NA             166/26                BCG (192)                                                                         100, 2--229

  Okazoe \[[@R46]\]             71                72, 41--95                  59/12                 Unknown regimen (31)                                                              9.8, 1.0--51.8

  Park \[[@R47]\]               70                66, 31--85                  53/8                  BCG (70)                                                                          60, 6--217

  Ruan \[[@R48]\]               126               64.5 (mean), 29--90         103/23                NA                                                                                NA

  Ben Abdelkrim \[[@R14]\]      71                63.1 (mean), 39--88         67/4                  NA                                                                                28, 3--77

  Bertz \[[@R18]\]              309               71.7, 38--87                237/72                BCG (309)                                                                         49, 5--172

  Ding \[[@R15]\]               332               67, 21--92                  273/59                NA                                                                                47, 2--124

  Mangrud \[[@R49]\]            193               74, 39--95                  148/45                BCG (NA)                                                                          75, 1--127

  Pan \[[@R50]\]                605               71 (mean), 23--92           511/94                MMC (272), doxorubicin (67), epirubicin (130), BCG (132)                          NA

  Özyalvaçli \[[@R16]\]         90                NA                          83/7                  NA                                                                                32.8, 36.2--103.6 (IQR)

  Poyet \[[@R17]\]              158               69.5, 32--92                131/43                NA                                                                                110.6, 32.4--266.8
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

NA: not available, BCG: bacille Calmette-Guérin, MMC: mitomycin C, IQR: interquartile range.

###### Tumor characteristics of the eligible studies

  Study                             T stage   Grade   Concomitant CIS   Multiplicity   Size   Tumor architecture   History                                                  
  --------------------------------- --------- ------- ----------------- -------------- ------ -------------------- --------- ----- ----- ----- ----- ----- ----- ---- ----- ----
  Asakura \[[@R20]\]                          61      43                30             63     11                   NA        NA    NA    NA    NA    NA    NA    NA   104   NA
  Lee \[[@R21]\]                    0         0       42                0              16     16                   30        2     42    0     NA    NA    26    6    17    15
  Pfister \[[@R22]\]                0         194     50                83             NA     NA                   NA        NA    163   81    152   92    NA    NA   244   0
  Tomobe \[[@R23]\]                 0         6       44                15             28     7                    NA        NA    26    24    NA    NA    NA    NA   34    16
  Wu \[[@R24]\]                     NA        NA      NA                NA             NA     0                    NA        NA    86    0     NA    NA    86    0    86    0
  Blanchet \[[@R25]\]               0         43      27                12             25     33                   63        7     30    17    NA    NA    NA    NA   70    0
  Kamai \[[@R26]\]                  NA        NA      NA                NA             NA     NA                   NA        NA    NA    NA    NA    NA    NA    NA   NA    NA
  Kilicli-Camur \[[@R27]\]          0         59      59                45             51     22                   NA        NA    NA    NA    NA    NA    NA    NA   60    58
  Sgambato \[[@R28]\]               0         42      54                13             51     32                   NA        NA    96    0     NA    NA    NA    NA   96    0
  Yan \[[@R29]\]                    0         215     55                57             183    30                   270       0     NA    NA    NA    NA    NA    NA   NA    NA
  Dybowski \[[@R30]\]               0         25      20                NA             NA     NA                   45        0     NA    NA    NA    NA    NA    NA   NA    NA
  Santos \[[@R31]\]                 0         56      103               61             98     0                    159       0     122   37    NA    NA    NA    NA   159   0
  Su \[[@R32]\]                     0         33      46                23             56     0                    NA        NA    43    36    65    14    56    23   79    0
  Mhawech \[[@R33]\]                0         0       49                0              38     11                   NA        NA    30    19    NA    NA    NA    NA   49    0
  Krüger \[[@R34]\]                 0         0       73                0              33     40                   NA        NA    27    46    NA    NA    NA    NA   73    0
  Theodoropoulos \[[@R35]\]         0         42      98                30             88     22                   NA        NA    NA    NA    NA    NA    NA    NA   140   0
  Gonzalez-Campora \[[@R36]\]^\*^   0         63      84                29             92     26                   NA        NA    NA    NA    57    90    NA    NA   147   0
  Quintero \[[@R37]\]^\*^           0         80      84                31             92     41                   NA        NA    NA    NA    109   55    NA    NA   164   0
  Yin \[[@R38]\]^\*^                0         54      47                0              59     42                   101       0     NA    NA    NA    NA    NA    NA   NA    NA
  Maeng \[[@R39]\]^\*^              0         38      17                10             22     23                   NA        NA    44    11    35    20    50    5    33    22
  Miyake \[[@R40]\]                 2         24      83                9              74     26                   98        11    54    55    87    22    NA    NA   109   0
  Seo \[[@R41]\]                    0         81      46                31             76     22                   129       0     36    84    60    57    104   15   101   28
  van Rhijn \[[@R10]\]              0         171     59                88             108    34                   218       12    165   65    NA    NA    NA    NA   230   0
  Behnsawy \[[@R42]\]               0         65      25                29             49     12                   76        14    46    44    72    18    80    10   90    0
  Wosnitzer \[[@R43]\]^\*^          9         5       18                0              0      32                   24        8     NA    NA    NA    NA    NA    NA   0     32
  Acikalin \[[@R6]\]                0         0       68                11             31     26                   NA        NA    23    45    16    52    NA    NA   NA    NA
  Chen \[[@R11]\]^\*^               0         19      53                16             38     18                   NA        NA    49    23    43    29    NA    NA   NA    NA
  Ogata \[[@R44]\]^\*^              0         41      2                 0              26     14                   43        0     43    0     24    19    43    0    43    0
  Oderda \[[@R45]\]                 0         121     115               53             76     63                   182       10    58    134   159   31    NA    NA   113   79
  Okazoe \[[@R46]\]^\*^             2         53      16                0              46     25                   NA        NA    34    37    54    12    58    13   44    27
  Park \[[@R47]\]                   0         0       61                0              0      61                   56        5     23    38    36    25    38    23   61    0
  Ruan \[[@R48]\]                   0         0       126               NA             NA     55                   126       0     75    51    NA    NA    NA    NA   NA    NA
  Ben Abdelkrim \[[@R14]\]          0         39      32                26             35     10                   NA        NA    NA    NA    NA    NA    NA    NA   71    0
  Bertz \[[@R18]\]                  0         0       309               0              89     220                  202       106   106   203   128   181   257   52   NA    NA
  Ding \[[@R15]\]                   0         204     128               114            168    50                   309       23    NA    NA    221   111   NA    NA   NA    NA
  Mangrud \[[@R49]\]                0         154     39                44             98     51                   171       22    92    73    NA    NA    NA    NA   193   0
  Pan \[[@R50]\]^\*^                0         336     231               38             256    311                  NA        NA    NA    NA    NA    NA    NA    NA   NA    NA
  Özyalvaçli \[[@R16]\]^\*^         0         41      49                0              45     45                   NA        NA    53    37    46    43    NA    NA   90    0
  Poyet \[[@R17]\]                  0         90      68                44             86     28                   12        146   115   43    NA    NA    151   7    158   0

^\*^Grading according to the 2004 WHO classification system: papillary urothelial neoplasm of low malignant potential, low grade and high grade.

CIS: carcinoma *in situ*, NA: not available.

Immunohistochemistry {#s2_2}
--------------------

Immunohistochemistry (IHC) was performed using tissue microarrays of 1--2 mm diameter samples of representative tissues and using slide mounted serial tissue sections in the other 34 studies. Fifteen of the 39 studies evaluated IHC staining in formalin-fixed paraffin-embedded tissue blocks, but did not identify the primary antibody used, and a wide range of antibody dilutions was reported (1/20 to 1/200). In 33 studies, immunopositivity was defined by the presence of nuclear staining, but the cutoff percentage for positive or negative expression (% IHC cutoff) and the reported percentage of Ki-67-positive cells varied widely among studies. Twenty studies reported blinded evaluation of Ki-67 expression (Table [4](#T4){ref-type="table"}).

###### Immunohistochemical analysis of the eligible studies

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                         Tissue section   Primary antibody   Dilution     Compartment   Definition of ki-67 index   \% IHC cut-off   \% ki-67 positive   Interpretation
  ----------------------------- ---------------- ------------------ ------------ ------------- --------------------------- ---------------- ------------------- ----------------
  Asakura \[[@R20]\]            All specimens    NA                 1:200        Nuclei        Yes                         5.35             50                  NA

  Lee \[[@R21]\]                All specimens    NA                 NA           Nuclei        Yes                         16               50                  Blind

  Pfister \[[@R22]\]            All specimens    Monoclonal         1:50         Nuclei        No                          10               70                  Blind

  Tomobe \[[@R23]\]             All specimens    NA                 1:200        Nuclei        Yes                         15.5             50                  NA

  Wu \[[@R24]\]                 All specimens    NA                 1:100        Nuclei        Yes                         10.9             50                  Blind

  Blanchet \[[@R25]\]           All specimens    Monoclonal         NA           NA            Yes                         13               18.5                Blind

  Kamai \[[@R26]\]              All specimens    Monoclonal         NA           Nuclei        Yes                         30               18.6                NA

  Kilicli-Camur \[[@R27]\]      All specimens    Monoclonal         1:30         Nuclei        Yes                         25               NA                  NA

  Sgambato \[[@R28]\]           All specimens    Monoclonal         1:100        Nuclei        Yes                         10               65.6                Blind

  Yan \[[@R29]\]                All specimens    NA                 NA           Nuclei        No                          25               34.2                NA

  Dybowski \[[@R30]\]           All specimens    Monoclonal         1:50         Nuclei        No                          30               50                  Blind

  Santos \[[@R31]\]             All specimens    NA                 1:50         Nuclei        Yes                         18               50                  NA

  Su \[[@R32]\]                 All specimens    NA                 1:50         Nuclei        Yes                         18               50                  NA

  Mhawech \[[@R33]\]            TM\              NA                 1:50         Nuclei        Yes                         NA               50                  Blind
                                (1.6 mm core)                                                                                                                   

  Krüger \[[@R34]\]             TM (2 × 2 mm)    Monoclonal         1:20         Nuclei        Yes                         Continuous       \-                  Blind

  Theodoropoulos \[[@R35]\]     All specimens    NA                 Prediluted   Nuclei        Yes                         8.6              50                  Blind

  Gonzalez-Campora \[[@R36]\]   All specimens    Monoclonal         1:20         Nuclei        Yes                         10               18.4                NA

  Quintero \[[@R37]\]           All specimens    Monoclonal         Prediluted   Nuclei        Yes                         13               10.4                NA

  Yin \[[@R38]\]                All specimens    Monoclonal         1:100        Nuclei        Yes                         20               24.8                NA

  Maeng \[[@R39]\]              All specimens    NA                 1:80         Nuclei        Yes                         25               36.4                NA

  Miyake \[[@R40]\]             All specimens    Monoclonal         Prediluted   Nuclei        Yes                         25               40.4                Blind

  Seo \[[@R41]\]                All specimens    Monoclonal         1:50         Nuclei        Yes                         25               36.4                NA

  van Rhijn \[[@R10]\]          All specimens    NA                 NA           NA            NA                          25               NA                  Blind

  Behnsawy \[[@R42]\]           All specimens    Monoclonal         1:200        Nuclei        Yes                         5                28.6                Blind

  Wosnitzer \[[@R43]\]          All specimens    Monoclonal         NA           NA            Yes                         10               50                  Blind

  Acikalin \[[@R6]\]            All specimens    Monoclonal         1:50         Nuclei        Yes                         10               69.1                Blind

  Chen \[[@R11]\]               All specimens    Monoclonal         1:50         Nuclei        Yes                         25               47.2                NA

  Ogata \[[@R44]\]              All specimens    Monoclonal         1:100        NA            No                          20               58.1                NA

  Oderda \[[@R45]\]             All specimens    Monoclonal         1:10         Nuclei        Yes                         20               NA                  NA

  Okazoe \[[@R46]\]             All specimens    Monoclonal         1:100        Nuclei        Yes                         18               29.6                Blind

  Park \[[@R47]\]               TM\              Monoclonal         1:200        Nuclei        Yes                         10.4             40                  Blind
                                (1 mm core)                                                                                                                     

  Ruan \[[@R48]\]               All specimens    Polyclonal         1:50         Nuclei        Yes                         10               55.6                Blind

  Ben Abdelkrim \[[@R14]\]      All specimens    NA                 1:50         Nuclei        Yes                         10               38                  Blind

  Bertz \[[@R18]\]              All specimens    Monoclonal         1:50         Nuclei        Yes                         15               64.4                NA

  Ding \[[@R15]\]               All specimens    Monoclonal         1:100        Nuclei        No                          25               32.5                NA

  Mangrud \[[@R49]\]            All specimens    NA                 NA           NA            Yes                         39               25                  NA

  Pan \[[@R50]\]                TM\              NA                 1:100        Nuclei        Yes                         20/80            NA                  Blind
                                (2 mm core)                                                                                                                     

  Özyalvaçli \[[@R16]\]         All specimens    Monoclonal         NA           Nuclei        Yes                         10               27.8                Blind

  Poyet \[[@R17]\]              TM\              NA                 1:50         NA            Yes                         10               38.4                NA
                                (1 mm core)                                                                                                                     
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

IHC: immunohistochemistry, NA: not available, TM: tissue microarray.

Study outcomes {#s2_3}
--------------

Of the 39 studies, the association of Ki-67 expression with recurrence-free survival (RFS) was reported in 34 (4,581 patients), with progression-free survival (PFS) in 21 (3,400 patients), with disease-specific survival (DSS) in six (1,505 patients), and with overall survival (OS) in two (356 patients) studies (Tables [5](#T5){ref-type="table"}--[8](#T8){ref-type="table"}). The most common cofactors included in the multivariate analysis of the risk of outcome were grade and T stage. Forest plots of the hazard ratios (HRs) reported in individual studies and those from the meta-analysis are shown in Figure [1](#F1){ref-type="fig"}. Despite the use of strict inclusion criteria, between-study heterogeneity was detected in the effect of Ki-67 expression on RFS and PFS, with *p* \<0.05 and I^2^ ≥ 50%.

###### Estimation of the hazard ratio for recurrence-free survival

  Study                       Analysis       HR estimation          Co-factors                                                                                                                                                        Analysis results
  --------------------------- -------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Asakura \[[@R20]\]          Multivariate   HR, 95% CI             T stage, grade, multiplicity, size                                                                                                                                Significant
  Lee \[[@R21]\]              Multivariate   HR, 95% CI             P53, bcl-2, cathepsin-D                                                                                                                                           Not significant
  Pfister \[[@R22]\]          Multivariate   HR, 95% CI             T stage, grade, multiplicity, size, p53, MDM2, p21                                                                                                                Not significant
  Tomobe \[[@R23]\]           Multivariate   HR, *p* value          T stage, grade, multiplicity, size, recurrence history, whole NOR, proliferating NOR, resting NOR                                                                 Not significant
  Wu \[[@R24]\]               Multivariate   HR, 95% CI             T stage, grade, p53, bcl-2                                                                                                                                        Significant
  Blanchet \[[@R25]\]         Univariate     Event no., *P* value   \-                                                                                                                                                                Not significant
  Kamai \[[@R26]\]            Multivariate   HR, 95% CI             Grade, p27, cyclin E                                                                                                                                              Significant
  Kilicli-Camur \[[@R27]\]    Univariate     Event no., *P* value   \-                                                                                                                                                                Significant
  Sgambato \[[@R28]\]         Multivariate   HR, 95% CI             Age, T stage, grade, p27, cyclin D1                                                                                                                               Significant
  Yan \[[@R29]\]              Multivariate   HR, 95% CI             T stage, p53                                                                                                                                                      Not significant
  Dybowski \[[@R30]\]         Univariate     Event no., *P* value   \-                                                                                                                                                                Significant
  Santos \[[@R31]\]           Multivariate   HR, 95% CI             T stage, grade, multiplicity, BCG, p53                                                                                                                            Significant
  Su \[[@R32]\]               Multivariate   HR, 95% CI             T stage, tumor architecture, p53, c-erbB-2                                                                                                                        Significant
  Krüger \[[@R34]\]           Multivariate   HR, 95% CI             Grade, p53                                                                                                                                                        Not significant
  Theodoropoulos \[[@R35]\]   Multivariate   HR, 95% CI             T stage, grade, apoptotic index, p53, bcl-2, VEGF, MVD, HIF-1α                                                                                                    Significant
  Quintero \[[@R37]\]         Multivariate   HR, 95% CI             Size                                                                                                                                                              Significant
  Maeng \[[@R39]\]            Univariate     HR, 95% CI             \-                                                                                                                                                                Significant
  Miyake \[[@R40]\]           Multivariate   HR, 95% CI             Grade, p53, HO-1                                                                                                                                                  Significant
  Seo \[[@R41]\]              Univariate     HR, 95% CI             \-                                                                                                                                                                Not significant
  van Rhijn \[[@R10]\]        Multivariate   HR, 95% CI             Age, sex, hospital, T stage, grade, concomitant CIS, multiplicity, size, EORTC risk score, *FGFR3*                                                                Not significant
  Behnsawy \[[@R42]\]         Univariate     HR, 95% CI             \-                                                                                                                                                                Not significant
  Wosnitzer \[[@R43]\]        Multivariate   HR, 95% CI             Age, sex, T stage, concomitant CIS, p53, stathmin, tau                                                                                                            Not significant
  Acikalin \[[@R6]\]          Multivariate   HR, 95% CI             Age, grade, size, multiplicity, mapsin                                                                                                                            Not significant
  Chen \[[@R11]\]             Multivariate   HR, 95% CI             Age, sex, T stage, grade, multiplicity, size, intravesical instillation, VEGF                                                                                     Significant
  Ogata \[[@R44]\]            Univariate     Event no., *P* value   \-                                                                                                                                                                Significant
  Oderda \[[@R45]\]           Multivariate   HR, 95% CI             Age, T stage, grade, ,multiplicity, size, p53                                                                                                                     Not significant
  Okazoe \[[@R46]\]           Univariate     HR, 95% CI             \-                                                                                                                                                                Not significant
  Park \[[@R47]\]             Multivariate   HR, 95% CI             p53, pRb, PTEN, p27, *FGFR3*, CD9                                                                                                                                 Not significant
  Ruan \[[@R48]\]             Multivariate   HR, 95% CI             Age, sex, grade, multiplicity, size, Sox2                                                                                                                         Significant
  Ben Abdelkrim \[[@R14]\]    Univariate     Event no., *P* value   \-                                                                                                                                                                Significant
  Bertz \[[@R18]\]            Multivariate   HR, 95% CI             Age, sex, grade, concomitant CIS, tumor architecture, p53, CK20                                                                                                   Not significant
  Ding \[[@R15]\]             Multivariate   HR, 95% CI             T stage, grade, concomitan CIS, multiplicity, size                                                                                                                Significant
  Pan \[[@R50]\]              Multivariate   HR, 95% CI             T stage, grade, multiplicity, size, intravesical instillation, p53, HSP27, COX2, cyclin D1, p16, pRb, p27, p21, EGFR, E-cadherin, EpCam, no. of altered markers   Significant
  Özyalvaçli \[[@R16]\]       Multivariate   HR, 95% CI             T stage, smoking, size, P16d                                                                                                                                      Not significant

HR: hazard ratio, CI: confidence interval, NOR: nucleolar organizer regions, BCG: bacille Calmette-Guérin, VEGF: vascular endothelial growth factor, MVD, microvessel density, HIF: hypoxia-inducible factor, CIS: carcinoma *in situ*, EORTC: European Organization for Research and Treatment of Cancer, EGFR: epithelial growth factor receptor.

###### Estimation of the hazard ratio for progression-free survival

  Study                         Analysis       HR estimation          Co-factors                                                                                                                                                        Analysis results
  ----------------------------- -------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Blanchet \[[@R25]\]           Multivariate   HR, 95% CI             T state, grade, concomitant CIS, multiplicity, size                                                                                                               Significant
  Kilicli-Camur \[[@R27]\]      Univariate     Event no., *P* value   \-                                                                                                                                                                Significant
  Santos \[[@R31]\]             Multivariate   HR, 95% CI             T stage, grade, multiplicity. BCG, p53                                                                                                                            Significant
  Mhawech \[[@R33]\]            Multivariate   HR, 95% CI             P53, p21, cyclin D1, p27, p16                                                                                                                                     Not significant
  Krüger \[[@R34]\]             Univariate     HR, 95% CI             \-                                                                                                                                                                Not significant
  Gonzalez-Campora \[[@R36]\]   Multivariate   HR, 95% CI             NA                                                                                                                                                                Significant
  Quintero \[[@R37]\]           Multivariate   HR, 95% CI             None                                                                                                                                                              Significant
  Yin \[[@R38]\]                Multivariate   HR, 95% CI             Age, T stage, grade, BIRC5-cytoplasmic labeling index, , BIRC5-nuclear labeling index                                                                             Not significant
  Seo \[[@R41]\]                Multivariate   HR, 95% CI             T stage, grade, tumor architecture, lymphovascular invasion                                                                                                       Significant
  van Rhijn \[[@R10]\]          Multivariate   HR, 95% CI             Age, sex, hospital, T stage, grade, concomitant CIS, multiplicity, size, EORTC risk score, *FGFR3*                                                                Not significant
  Acikalin \[[@R6]\]            Multivariate   HR, 95% CI             Age, grade, size, multiplicity, mapsin                                                                                                                            Not significant
  Chen \[[@R11]\]               Multivariate   HR, 95% CI             Age, sex, T stage, grade, multiplicity, size, intravesical instillation, VEGF                                                                                     Significant
  Oderda \[[@R45]\]             Multivariate   HR, 95% CI             Age, T stage, grade, ,multiplicity, size, p53                                                                                                                     Not significant
  Park \[[@R47]\]               Multivariate   HR, 95% CI             p53, pRb, PTEN, p27, *FGFR3*, CD9                                                                                                                                 Not significant
  Ben Abdelkrim \[[@R14]\]      Univariate     Event no., *P* value   \-                                                                                                                                                                Not significant
  Bertz \[[@R18]\]              Multivariate   HR, 95% CI             Age, sex, grade, concomitant CIS, tumor architecture, p53, CK20                                                                                                   Significant
  Ding \[[@R15]\]               Multivariate   HR, 95% CI             T stage, grade, concomitan CIS, multiplicity, size                                                                                                                Significant
  Mangrud \[[@R49]\]            Univariate     HR, 95% CI             \-                                                                                                                                                                Significant
  Pan \[[@R50]\]                Multivariate   HR, 95% CI             T stage, grade, multiplicity, size, intravesical instillation, p53, HSP27, COX2, cyclin D1, p16, pRb, p27, p21, EGFR, E-cadherin, EpCam, no. of altered markers   Significant
  Özyalvaçli \[[@R16]\]         Univariate     Event no., *P* value   \-                                                                                                                                                                Not significant
  Poyet \[[@R17]\]              Multivariate   HR, 95% CI             Grade, tumor architecture, Cx43                                                                                                                                   Not significant

HR: hazard ratio, CI: confidence interval, CIS: carcinoma *in situ*, BCG: bacille Calmette-Guérin, NA: not available, EORTC: European Organization for Research and Treatment of Cancer, VEGF: vascular endothelial growth factor, EGFR: epithelial growth factor receptor.

###### Estimation of the hazard ratio for disease-specific survival

  Study                  Analysis       HR estimation          Co-factors                                                                                                                                                        Analysis results
  ---------------------- -------------- ---------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------
  Yin \[[@R38]\]         Multivariate   HR, 95% CI             Age, T stage, grade, BIRC5-cytoplasmic labeling index, , BIRC5-nuclear labeling index                                                                             Not significant
  van Rhijn \[[@R10]\]   Multivariate   HR, 95% CI             Age, sex, hospital, T stage, grade, concomitant CIS, multiplicity, size, EORTC risk score, *FGFR3*                                                                Not significant
  Acikalin \[[@R6]\]     Univariate     Event no., *P* value   \-                                                                                                                                                                Not significant
  Oderda \[[@R45]\]      Multivariate   HR, 95% CI             Age, T stage, grade, ,multiplicity, size, p53                                                                                                                     Not significant
  Bertz \[[@R18]\]       Multivariate   HR, 95% CI             Age, sex, grade, concomitant CIS, tumor architecture, p53, CK20                                                                                                   Significant
  Pan \[[@R50]\]         Multivariate   HR, 95% CI             T stage, grade, multiplicity, size, intravesical instillation, p53, HSP27, COX2, cyclin D1, p16, pRb, p27, p21, EGFR, E-cadherin, EpCam, no. of altered markers   Significant

HR: hazard ratio, CI: confidence interval, CIS: carcinoma *in situ*, EORTC: European Organization for Research and Treatment of Cancer, EGFR: epithelial growth factor receptor.

###### Estimation of the hazard ratio for overall survival

  Study                 Analysis       HR estimation   Co-factors                                      Analysis results
  --------------------- -------------- --------------- ----------------------------------------------- ------------------
  Quintero \[[@R37]\]   Multivariate   HR, 95% CI      Size, p27                                       Significant
  Oderda \[[@R45]\]     Multivariate   HR, 95% CI      Age, T stage, grade, ,multiplicity, size, p53   Significant

HR: hazard ratio, CI: confidence interval.

![Forest plots of the hazard ratios\
High Ki-67 expression indicated poor bladder cancer prognosis. (**A**) Recurrence-free survival, (**B**) progression-free survival, (**C**) disease-specific survival, (**D**) overall survival. Between-study heterogeneity was detected in the effect of Ki-67 expression on RFS and PFS.](oncotarget-08-100614-g001){#F1}

RFS {#s2_4}
---

Overall, the pooled HR for RFS in 34 studies was 1.78 (95% CI, 1.48--2.15), suggesting that high Ki-67 expression indicated poor bladder cancer prognosis. However, significant heterogeneity was observed in the studies (I^2^ = 80%, *p* \< 0.00001) (Figure [1A](#F1){ref-type="fig"}). Subgroup meta-regression by publication year, region, number of patients, HR estimation, and analysis results identified analysis results as the only possible explanation for heterogeneity (*p* \< 0.0001, Table [9](#T9){ref-type="table"}). The other variables in the subgroup analyses did not include any heterogeneity of data.

###### Subgroup analysis for recurrence-free survival

                     No. of included articles   No. of cases   Pooled HR (95% CI)   Chi^2^ (*p* value)    I^2^   *P*~h~^\*^
  ------------------ -------------------------- -------------- -------------------- --------------------- ------ ------------
  Publication year                                                                                               0.1633
   1997--2009        16                         1,816          2.05 (1.52--2.76)    92.96 (\< 0.00001)    84%    
   2010--2015        18                         2,765          1.58 (1.26--1.96)    37.18 (0.003)         54%    
  Region                                                                                                         0.7686
   Asia              16                         2,167          1.66 (1.29--2.13)    33.06 (0.005)         55%    
   Europe            14                         1,825          1.91 (1.41--2.58)    76.87 (\< 0.00001)    83%    
   America           4                          589            1.81 (1.04--3.15)    9.93 (0.02)           70%    
  No. of patients                                                                                                0.3895
   \< 100            18                         1,189          1.95 (1.44--2.65)    69.11 (\< 0.00001)    75%    
   ≥ 100             16                         3,392          1.66 (1.36--2.03)    37.44 (0.001)         60%    
  HR estimation                                                                                                  0.5542
   Univariate        9                          763            1.99 (1.30--3.05)    29.03 (0.0003)        72%    
   Multivariate      25                         3,818          1.72 (1.40--2.12)    111.81 (\< 0.00001)   79%    
  Analysis results                                                                                               \< 0.0001
   Not significant   16                         2,091          1.22 (1.05--1.43)    22.48 (0.10)          33%    
   Significant       18                         2,490          2.28 (1.93--2.70)    22.27 (0.17)          24%    

HR: hazard ratio, CI: confidence interval.

P~h~^\*^ for heterogeneity between subgroups with meta-regression analysis.

PFS {#s3}
===

A meta-analysis of 21 studies found that high Ki-67 expression was significantly associated with poor PFS (pooled HR, 1.28; 95% CI, 1.13--1.44). However, the Cochrane *Q* test (*p* \< 0.00001) and an I^2^ = 75% could not exclude significant heterogeneity (Figure [1B](#F1){ref-type="fig"}). Meta-regression analysis revealed that region accounted for part of the study heterogeneity for PFS (*p* = 0.00471, Table [10](#T10){ref-type="table"}). In addition, analysis results was found to significantly affect the relationship between Ki-67 expression and PFS (*p* \< 0.0001). Other variables included in this subgroup analysis did not include any heterogeneity of data.

###### Subgroup analysis for progression-free survival

                     No. of included articles   No. of cases   Pooled HR (95% CI)   Chi^2^ (*p* value)   I^2^   *P*~h~^\*^
  ------------------ -------------------------- -------------- -------------------- -------------------- ------ ------------
  Publication year                                                                                              0.1633
   1997--2009        8                          881            1.08 (0.97--1.19)    37.11 (\< 0.00001)   81%    
   2010--2015        13                         2,519          2.11 (1.62--2.75)    11.71 (0.47)         0%     
  Region                                                                                                        0.0471
   Asia              6                          1,309          2.16 (1.19--3.93)    8.96 (0.11)          44%    
   Europe            15                         2,091          1.17 (1.05--1.30)    55.75 (\< 0.00001)   75%    
  No. of patients                                                                                               0.2529
   \< 100            8                          563            1.53 (0.91--2.59)    18.15 (0.01)         61%    
   ≥ 100             13                         2,837          2.26 (1.50--3.43)    54.85 (\< 0.00001)   78%    
  HR estimation                                                                                                 0.418
   Univariate        5                          545            1.61 (0.97--2.69)    10.50 (0.03)         62%    
   Multivariate      16                         2,855          2.11 (1.41--3.15)    62.59 (\< 0.00001)   76%    
  Analysis results                                                                                              \< 0.0001
   Not significant   10                         1,102          1.00 (0.98--1.02)    7.10 (0.63)          0%     
   Significant       11                         2,298          3.02 (1769--5.21)    66.75 (\< 0.00001)   85%    

HR: hazard ratio, CI: confidence interval, NMIBC: non-muscle invasive bladder cancer.

P~h~^\*^ for heterogeneity between subgroups with meta-regression analysis.

DSS {#s4}
===

A meta-analysis of six studies found that high Ki-67 expression was significantly associated with poor DSS (pooled HR, 2.24; 95% CI, 1.47--3.39). No significant study heterogeneity was found (I^2^ = 0%, *p* = 0.73; Figure [1C](#F1){ref-type="fig"}).

OS {#s5}
==

Meta-analysis of the two studies evaluating the association of ki-67 expression with OS found that a high Ki-67 expression predicted a worse outcome, with a pooled HR of 2.29 (95% CI, 1.24--4.22). Inter-study heterogeneity was not significant (I^2^ = 12%, *p* = 0.29) (Figure [1D](#F1){ref-type="fig"}).

Sensitivity analysis {#s5_1}
--------------------

One-way sensitivity analyses were conducted by stepwise exclusion of single studies and recalculating the pooled HR for the remaining studies. No significant differences were observed among the results obtained at each step of the analysis (data not shown), demonstrating that the overall results of the meta-analysis were statistically reliable.

Publication bias {#s5_2}
----------------

Because fewer than 10 studies were included in meta-analyses of DSS and OS, it was not reasonable to estimate the potential for publication bias. No obvious asymmetry was evident in any of the funnel plots shown in Figure [2](#F2){ref-type="fig"}. The *p*-values of the Begg tests for RFS and PFS were \> 0.05 (*p* = 0.4676 for RFS and 0.4324 for PFS), which confirmed the funnel plot symmetry and lack of evidence of publication bias.

![Begg tests for (**A**) recurrence-free survival and (**B**) progression-free survival confirmed the funnel plot symmetry and lack of evidence of publication bias. Fewer than 10 studies were included in meta-analyses of (**C**) disease-specific survival and (**D**) overall survival.](oncotarget-08-100614-g002){#F2}

DISCUSSION {#s6}
==========

About 75% of newly diagnosed bladder cancers are NMIBC localized in the subepithelial connective tissue \[[@R8]\]. After initial TURBT, NMIBC patients undergo cystoscopy every 3 months for the first year to monitor recurrence and progression. This protocol is painful and is also a financial burden; however, because progression to MIBC has a bad prognosis for the patients, ongoing cystoscopy and radiological evaluation are required. Early cystectomy for high risk T1 bladder cancer patients who are expected to progress is important because it can increase survival. On the other hand, radical cystectomy is a surgical procedure with many complications and requires use of urostomy bags or clean intermittent catheterizations, both of which have negative effects on daily activities. Efforts to distinguish candidates for early cystectomy or bladder preservation are complicated by the heterogeneous clinical behavior of bladder cancer.

Until recently, predicting the progression from NMIBC to MIBC has relied on clinicopathological variables, such as tumor size, grade, multiplicity, and diagnosis of CIS. However, even in cases of the same stage and grade of NMIBC, the clinical course can vary from no recurrence to rapid progression, making it difficult to predict the course. In addition, inter-pathologist variation in interpretation of TURBT specimens can occur because of malorientation, cautery artifacts, and other reasons. Given the current situation, reliable molecular markers would assist in making clinical decisions.

Previous studies of tumorigenesis indicated that changes at the molecular level precede changes in cellular morphology \[[@R9]\]. Changes in gene expression in multiple molecular pathways have been related to the development of bladder cancer. Ki-67 has been associated with expression of oncogenes or tumor suppressor genes, such as Connexin 43, Sox2, G protein-coupled receptor 87, heme oxygenase-1, p53, and p27 \[[@R17], [@R26], [@R37], [@R40], [@R46], [@R48]\]. IHC assays of proliferation markers, such as the Ki-67 and fibroblast growth factor receptor (FGFR)-3 are available in most pathology laboratories and have high reproducibility \[[@R10], [@R11]\]. IHC is currently used worldwide by over 90% of pathologists to diagnose bladder cancer, and Ki-67 is already used as a prognostic marker in over 84% of specimens in Europe \[[@R12]\]. Another advantage of this biologic marker is that objective measurements are possible and changes in expression can be compared after the therapeutic intervention.

Despite many advantages, biologic markers are not widely used to make clinical decisions because difficulties in making direct comparisons of study results have resulted in lack of consensus on their usefulness. In this meta-analysis, the overexpression threshold varied from 5% to 25% and the variation in positive Ki-67 expression was from 10% to 70 percent. Reasons for the inconsistency of previous study results include different follow-up protocols after TURBT, and differences in patient ethnicity, geography, tumor stage, tissue sectioning methods, and the primary antibodies and antibody dilutions used in each study \[[@R6]\]. The importance of these differences was apparent in the inter-study heterogeneity detected in the meta-analysis, with I^2^ values of 80% in RFS and 75% in PFS. To the best of our knowledge, this was the first meta-analysis of Ki-67 in bladder cancer. To determine the origins of the heterogeneity, we performed a meta-regression including publication year, region, HR estimation, and analysis results. Only analysis results were significantly associated with heterogeneity of studies reporting RFS. Although region might have accounted for part of the inter-study heterogeneity, analysis results was observed to significantly affect the relationship of Ki-67 expression and PFS.

As a proliferation-associated nuclear antigen, Ki-67 is expressed in all phases of the cell cycle except G~0~. The normal bladder uroephithelium has a very low proliferation rate \[[@R13]\], increased proliferation may signal recurrence rate, and high Ki-67 expression has a poor prognosis for patients with bladder cancer. Bladder tumors with Ki-67 expression have aggressive behaviors, such as multifocality, concomitant CIS, and increased EORCT risk scores, in addition to higher grade/stage \[[@R14], [@R15]\]. Because Ki-67 is a cellular proliferation marker, some studies claim that it is more closely related to the recurrence of NMIBC rather than progression to MIBC \[[@R14], [@R16]\]. Other studies reported that Ki-67 was related not only to recurrence but also to progression and survival \[[@R15], [@R17], [@R18]\]. Even though a consensus on the prognosis of Ki-67 expression has not been reached, this meta-analysis found that patients with high Ki-67 expression had significantly higher recurrence and progression rates than those with low expression. Even though the meta-analysis of DSS included only six studies and that of OS only two, patients with high Ki-67 expression had a significantly worse prognosis.

There were two notable study limitations. The first was study heterogeneity, which is common to meta-analyses of prognostic marker studies. Even though we applied strict inclusion and exclusion criteria to all study stages, and the selected studies included patient populations with similar T stage and grade, the variables evaluated study was different and diverse. Second, because of the strict selection criteria, we were not able to perform Begg tests as fewer than 10 studies were included in the DSS and OS meta-analysis. Consequently, while the analysis generated symmetrical inverted funnel plots, the results should be interpreted with care because of publication bias.

MATERIALS AND METHODS {#s7}
=====================

This meta-analysis was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines \[[@R19]\].

Search strategy {#s7_1}
---------------

Embase, Scopus, and PubMed were searched for articles published in English to March 28, 2016 using the keywords "bladder cancer" and "Ki-67." The titles and abstracts of the retrieved articles were reviewed independently by two authors (KK and CWJ) to minimize bias and to improve reliability. The reference lists of the retrieved articles were manually searched for potentially eligible studies that were not included in the initial database search. The full texts of the selected articles were independently screened by the same authors. Disagreements between the reviewers were resolved by consensus.

Study selection {#s7_2}
---------------

The PRISMA flow chart of the systematic literature search and study selection is shown in Figure [3](#F3){ref-type="fig"}. The initial searches retrieved 1,959 articles. Of these, 1,059 were excluded as duplicate publications and an additional 575 were excluded after reviewing the abstracts. The full texts of the remaining 325 articles were reviewed, and an additional 286 articles that did not satisfy the inclusion criteria were excluded. A total of 39 articles including 5,229 patients, ranging from 32 to 605 per study were finally included in the analysis \[[@R6], [@R10], [@R11], [@R14]--[@R18], [@R20]--[@R50]\].

![The PRISMA flow chart](oncotarget-08-100614-g003){#F3}

Inclusion and exclusion criteria {#s7_3}
--------------------------------

Following the PRISMA guidelines, the study population, intervention, comparator, outcome, and study design (PICOS) were used to define study eligibility \[[@R19]\]. In this analysis, these were defined as *Population*, patients with NMIBC; *Intervention*: TURBT; *Comparator*, Ki-67 expression; *Outcome*, recurrence, progression, cancer-specific mortality, and any-cause mortality; *Study design*, univariate and/or multivariate Cox regression analysis. Strict, well-defined inclusion and exclusion criteria were intended to limit heterogeneity across studies and facilitate obtaining clinically meaningful results in this meta-analysis of prognostic marker studies \[[@R51]\]. The eligibility criteria were as follows: publication as an original article in English language; included human research subjects who were NMIBC patients and treated with TURBT; reported the histologic type as urothelial carcinoma (UC); evaluated Ki-67 expression in bladder cancer tissue by IHC; and investigated the association of Ki-67 expression level and survival outcomes. Eligible articles reported Kaplan--Meier/Cox regression-derived results of the prognostic value of Ki-67 on outcomes following the REporting recommendations for tumor MARKer prognostic studies (REMARK) guidelines for assessment of prognostic markers \[[@R52]\].

Studies were excluded if they were: letters, commentaries, case reports, reviews, or conference abstracts (because of limited data); studies conducted in animals or cell lines; studies using other than survival analyses.

If the same patient series was included in more than one publication, only the most informative or complete report was included to avoid duplication of the survival data. Two reviewers (CK and HHK) independently determined study eligibility. Discrepant opinions were resolved by discussion.

End points {#s7_4}
----------

The primary outcome measures were RFS, PFS, DSS, and OS. Survival was defined as the time from TURBT to the last follow-up. In the meta-analysis, recurrence was the development of histologically confirmed UC on follow-up after complete tumor resection. Disease-specific death was any death because of bladder cancer in patients with documented metastatic or recurrent disease. Compared with the primary tumor, progression was defined in individual studies as development of a higher stage \[[@R6], [@R14]\]; development of a higher stage and/or grade \[[@R27], [@R31]\]; development of a higher stage and/or grade as well as development of regional or distant metastases \[[@R25]\]; development of a higher stage or metastasis \[[@R10], [@R16], [@R17], [@R33], [@R36], [@R37], [@R41]\], or development of a higher stage and muscle invasive cancer (≥ T2), distant metastasis, or death from bladder cancer \[[@R11]\]. Additional definitions of progression included development of MIBC (≥ T2) \[[@R34], [@R45], [@R47]\] and development of MIBC (≥ T2) and/or metastasis \[[@R15], [@R49], [@R50]\].

Data extraction {#s7_5}
---------------

Two reviewers (KK and JHK) extracted the study characteristics and outcome data, which were subsequently crosschecked to ensure their accuracy. Any discrepancies in extracting data were resolved by discussion. Authors of eligible studies were not contacted for additional data. The data retrieved following the REMARK guidelines were: the name of first author, country and year of publication, geographic location, study design, and recruitment period; the study population sample size, mean or median age, gender distribution, inclusion and exclusion criteria, treatment administered, endpoint definition, and follow-up period; tumor characteristics including stage, and grade; IHC data including cutoff value of positive expression, the antibodies used; adoption of a blinded evaluation method; and statistical data including survival curves, data including the total number of case and control participants, and HRs with confidence intervals (CIs). Discrepancies were resolved by discussion.

Statistical analysis {#s7_6}
--------------------

The meta-analysis was carried out with Review Manager software (RevMan 5; The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark) and R 2.13.0 (R Development Core Team, Vienna, Austria, <http://www.R-project.org>).

Primary analysis {#s7_7}
----------------

Study and pooled estimates were presented as forest plots. Survival outcome data were synthesized using the time-to-event HR as the operational measure. The method used to estimate the HR of each publication depended on the data provided. If HRs and the corresponding standard errors were not directly reported, then previously reported indirect methods were used to extract the logHR and variance because of the lack of previously published prognostic values \[[@R53]--[@R55]\]. A DerSimonian and Laird random effects model was used to obtain the summary HRs and 95% CIs.

Assessment of heterogeneity {#s7_8}
---------------------------

Heterogeneity of combined HRs was evaluated by the chi-square test and Higgins I-squared statistic. With the chi-square test, heterogeneity was significant when the *p*-value was \< 0.05. I^2^ described the proportion of total variation in meta-analysis estimates that was caused by inter-study heterogeneity, rather than sampling error. It can take a value from 0% to 100%; increasing I^2^ values indicated increasing between-study heterogeneity. An I^2^ value above 50% was considered as having notable heterogeneity \[[@R56], [@R57]\], and if found, a subgroup meta-regression analysis was carried out to identify the source of the heterogeneity.

Publication bias {#s7_9}
----------------

Publication bias was evaluated with funnel plots. In the absence of bias, the plots should resemble a symmetrical, inverted funnel and in the presence of bias, they should appear skewed and asymmetrical \[[@R57]\]. If more than 10 studies were included in the meta-analysis, then the Begg rank correlation test was also used to evaluate publication bias \[[@R58]\]. Bias was assumed if the *p*-value was \< 0.05.
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